DYAI – dyadic international, inc. (US:NASDAQ)

News

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology [Yahoo! Finance]
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic International Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Dyadic International, Inc. (NASDAQ: DYAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Dyadic International Inc (DYAI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com